Reed Michael Lee 4

What Happened
Reed Michael Lee, a director of Nutex Health, was granted 823 restricted stock units (RSUs) on April 23, 2026. The reported acquisition price is $0.00 (a typical notation for awards), and the filing classifies the transaction as a derivative award rather than a cash purchase or sale. The RSUs represent contingent rights to receive one share of Nutex Health common stock per RSU upon vesting.

Key Details

• Transaction date: April 23, 2026; Form 4 filed April 24, 2026 (appears timely).
• Award: 823 RSUs; reported price $0.00 and reported value $0 (award/derivative).
• Vesting: 100% vests on April 23, 2027. If the reporting person leaves without cause during the vesting period, RSUs vest pro rata for actual time in service. (See footnotes F1 and F2.)
• Shares owned after transaction: not specified in the provided filing details.
• No 10b5-1 plan, cashless exercise, or tax-withholding actions reported in the provided notes.

Context
RSU grants are compensation awards that do not involve an immediate cash purchase or sale; they convert into shares (and potential market exposure) only if and when they vest. This grant is routine compensation/retention for an executive and should be interpreted as an award schedule rather than an immediate bullish or bearish market signal.